GI 254023X
(Synonyms: (ALPHAR)-N-[(1S)-2,2-二甲基-1-[(甲基氨基)羰基]丙基]-ALPHA-[(1S)-1-(甲酰基羟基氨基)乙基]苯戊酰胺,GI4023; SRI028594) 目录号 : GC14578
An ADAM10 inhibitor
Cas No.:260264-93-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1, 2]: | |
|
Cell lines |
Jurkat cells; Human pulmonary artery endothelial cells (HPAECs) |
|
Preparation method |
The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
20 μM, 16-18h |
|
Applications |
In Jurkat cells, GI 254023X inhibited cell proliferation and increased apoptosis in a concentration-dependent manner. Compared with control group, GI 254023X up-regulated the expression of Notch1 while down-regulated the expression of cleaved Notch1 in a time-dependent way. GI254023X also reduced the levels of MCL-1 and Hes-1 mRNA transcripts. In human pulmonary artery endothelial cells (HPAECs), GI254023X inhibited VE-cadherin cleavage and completely protected HPAECs from Hla-mediated barrier disruption. |
| Animal experiment [2]: | |
|
Animal models |
BALB/c mice injected with endotoxin-free recombinant Hla |
|
Dosage form |
200 mg/kg/day, dilution in 0.1 M carbonate buffer, 3-day period, intraperitoneal injection |
|
Application |
In BALB/c mice injected with endotoxin-free recombinant Hla, GI254023X enhanced vascular integrity, manifest by limited dye extravasation, suggested that GI254023X may afford protection against lethal infection. Mice were treated with either DMSO or GI254023X then infected with 5×107 CFUs S. aureus Newman. GI254023X-treated mice were less ill in appearance and demonstrated prolongation of time to death. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Ma S1,2, Xu J1, Wang X1,2, et al. Effect of ADAM10 Inhibitor GI254023X on Proliferation and Apoptosis of Acute T-Lymphoblastic Leukemia Jurkat Cells In Vitro and Its Possible Mechanisms. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Aug;23(4):950-5. [2] Powers ME, Kim HK, Wang Y, Bubeck Wardenburg J.ADAM10 mediates vascular injury induced by Staphylococcus aureus α-hemolysin. J Infect Dis. 2012;206(3):352-6. |
|
Description:IC50: 5.3 nM (ADAM10)
A Disintegrin and metalloproteinase domain-containing protein 10, also known as ADAM10 or CDw156 or CD156c is a protein that in humans is encoded by the ADAM10 gene. ADAM10 (EC#: 3.4.24.81) is a sheddase, and has a broad specificity for peptide hydrolysis reactions (http://en.wikipedia.org/wiki/ADAM10). GI 254023X, synthesized by GSK, was reported to inhibit ADAM10 100-fold over ADAM17. GI 254023X could reduce constitutive cleavage of fractilkine from ECV-304 transfectants [1].
In vitro: Previusl study reported that compound GI254023X possessed comparable inhibitory potency for ADAM10 only and blocked TACE with more than 100-fold reduced potency [2].
In vivo: To examine the ability of GI254023X to inhibit Hla-mediated endothelial barrier disruption in vivo, mice treated for a 3-day period with GI254023X via intraperitoneal injection were subjected to a Miles assay following subcutaneous injection of recombinant toxin. Resutls showed that although all experimental animals succumbed to the lethal challenge, GI254023X-treated mice were less ill in appearance and demonstrated prolongation of time to death [3].
Clinical trial: GI254023X is currently in the preclinical development and no clinical trial is ongoing..
References
[1] Koichi Yokota, and Shin-Ichiro Nishimura. MMP/ADAM inhibitors: therapeutic potential for psoriasis. Expert Opin. Ther. Patents. 2005;15:421-435
[2] Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, Kallen KJ, Rose-John S, Ludwig A.The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood. 2003;102(4):1186-95.
[3] Powers ME, Kim HK, Wang Y, Bubeck Wardenburg J.ADAM10 mediates vascular injury induced by Staphylococcus aureus α-hemolysin. J Infect Dis. 2012;206(3):352-6.
| Cas No. | 260264-93-5 | SDF | |
| 别名 | (ALPHAR)-N-[(1S)-2,2-二甲基-1-[(甲基氨基)羰基]丙基]-ALPHA-[(1S)-1-(甲酰基羟基氨基)乙基]苯戊酰胺,GI4023; SRI028594 | ||
| 化学名 | (2R)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-2-[(1S)-1-[formyl(hydroxy)amino]ethyl]-5-phenylpentanamide | ||
| Canonical SMILES | CC(C(CCCC1=CC=CC=C1)C(=O)NC(C(=O)NC)C(C)(C)C)N(C=O)O | ||
| 分子式 | C21H33N3O4 | 分子量 | 391.5 |
| 溶解度 | DMF: 1 mg/mL,Ethanol: 1 mg/mL,Ethanol:PBS (pH 7.2) (1:6): 0.14mg/mL | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5543 mL | 12.7714 mL | 25.5428 mL |
| 5 mM | 0.5109 mL | 2.5543 mL | 5.1086 mL |
| 10 mM | 0.2554 mL | 1.2771 mL | 2.5543 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。